Characteristics of patients diagnosed with cervical cancer in Brazil: preliminary results of the prospective cohort EVITA study (EVA001/LACOG 0215)
Angélica Nogueira Rodrigues, Andréia Cristina de Melo, Aknar Freire de Carvalho Calabrich, Eduardo Cronenberge, Kátia Luz Torres, Fernanda Damian, Rachel Cossetti, Carla Rameri Alexandre Silva de Azevedo, Allex Jardim da Fonseca, Yeni Nerón, João Nunes, André Lopes, Felipe Thomé, Renato Leal, Giuliano Borges, Arthur Ferreira da Silva, Matheus Füehr Rodrigues, Paulo Ricardo Santos Nunes Filho, Facundo Zaffaroni, Raquel Dal Sasso Freitas, Gustavo Werutsky and Fernando Maluf. DOI: http://doi.org/10.1136/ijgc-2021-002972 Full link: https://ijgc.bmj.com/content/early/2021/12/28/ijgc-2021-002972
A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)
Fernando C. Maluf, Fabio A. Schutz, Eduardo H. Cronemberger, Murilo de A. Luz, Suelen P. S. Martins, David Q. B. Muniz, Diogo A. Bastos, Flavio M. Cárcano, Oren Smaletz, Andrey Soares, Fábio A. Peixoto, Andrea J. Gomes, Felipe M. Cruz, Fabio A. Franke, Daniel Herchenhorn, Telma M. dos Santos, Vanessa de C. Fabricio, Rosemarie Gidekel, Gustavo Werutsky, Rafaela G. de Jesus, Vinicius C. Souza, André P. Fay DOI: https://doi.org/10.1016/j.ejca.2021.08.032 Full link: https://www.sciencedirect.com/science/article/pii/S0959804921005591
Epidemiological characteristics and survival of patients with diffuse glioma in Brazil: preliminary results of a multicentric retrospective study – LACOG 0619
Camilla Yamada, Carolina Vasques, Rodrigo Coutinho, Marcos Maldaun, Clarissa Baldotto, Fabiana Viola, Fernando Maluf, Vanessa Santos, Carolina Pessoa, Patrícia Pacheco, Danielli Matias, Daniela Oliveira, Fernanda Peria, Rafaela de Jesus, Taiane Rebelatto, Suzana Malheiros DOI: https://doi.org/10.1093/neuonc/noab196.340 Full link: https://academic.oup.com/neuro-oncology/article-abstract/23/Supplement_6/vi86/6426546
Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean
Gustavo Werutsky, Carlos H Barrios, Andres F Cardona, André Albergaria, Alfonso Valencia, Carlos G Ferreira, Christian Rolfo, Evandro de Azambuja, Gabriel A Rabinovich, Georgina Sposetti, Oscar Arrieta, Rodrigo Dienstmann, Taiane F Rebelatto, Valeria Denninghoff, Veronica Aran, Eduardo Cazap DOI: https://doi.org/10.1016/S1470-2045(21)00523-4 Full link: https://www.sciencedirect.com/science/article/abs/pii/S1470204521005234?dgcid=coauthor
Cancer control in Latin America and the Caribbean: recent advances and opportunities to move forward
Carlos H Barrios, Gustavo Werutsky, Alejandro Mohar, Ana S Ferrigno, Bettina G Müller, Brittany L Bychkovsky, Carlos José Castro, Claudia J Uribe, Cynthia Villarreal-Garza, Enrique Soto-Perez-de-Celis, Francisco Gutiérrez-Delgado, Ji Seok Kim, Julia Ismael, Lucia Delgado, Luiz A Santini, Nelson Teich, Pamela C Chavez, Pedro E R Liedke, Pedro Exman, Romualdo Barroso-Sousa, Stephen D Stefani, Suyapa A Bejarano Cáceres, Taiane F Rebelatto, Tania Pastrana, Yanin Chavarri-Guerra, Yolanda Vargas, Eduardo Cazap DOI: https://doi.org/10.1016/S1470-2045(21)00492-7 Full link: https://www.sciencedirect.com/science/article/pii/S1470204521004927?dgcid=coauthor
London Global Cancer Week 2021
Sign up for London Global Cancer Week 2021! Renowned international speakers will be discussing the impact of the Pandemic and the post-COVID-19 changes in the area of oncology in Latin America. The online event will take place on Friday, November 19th, 2 pm - 4 pm (GMT) - 10 am -12 am (BRT).
Memo inOncology SPECIAL ISSUE congress report ASCO 2021- Lung Cancer is now available!
This report highlights immunotherapeutic standards in early-stage lung cancer. Moreover, strategies against sensitizing and resistance-mediating EGFR mutations as well as current perspectives regarding KRAS, MET, ROS1 and HER2 mutations are covered. Furthermore, immunotherapies and immunosupportive mechansims via e.g. anti-angiogenesis are addressed. Last but not least, this special issue includes a section about new vistas for patients with SCLC and expert interviews regarding resistance as one of the biggest challenges with targeted therapies. As an additional feature, you will find expert video interviews with Martin Reck, Luis Paz-Ares, David T. Cooke, Donald Harvey, and Ferdinandos Skoulidis on different conference highlights on our website. Download the full report
The Projeto Cura Institute has launched a campaign for donations: “Together we can be stronger than Cancer”
Brazilian researchers are asking for funding for a study that is close to identifying the best course of preoperative treatment for breast cancer and which will have benefits for women around the world. The Projeto Cura Institute has launched a campaign for donations from the public: "Together we can be stronger than Cancer", which is aiming to raise enough funds to enable data to be processed for one year as part of a completely Brazilian-based piece of research into the sequences for the treatment of HER2-negative type breast cancer. The NeoSamba study is a randomized clinical trial, which is now in phase 3. It is examining a new sequence of treatment including neoadjuvant chemotherapy (before breast surgery) and intends to monitor the treatment of almost 500 women over three years. During ASCO, the conference of the American Society of Clinical Oncology, in 2018, Dr. José Bines, the principal investigator for the study, talked about the conclusion of Phase II of NeoSamba. The research was conducted by the National Cancer Institute (INCA) and it investigated the cases of 118 patients to assess whether changing the order of the drugs in the anthracyclines and taxane classes (some of the most commonly-used drugs for chemotherapy) would
Innovation in Breast Cancer Symposium – Lisbon edition 2021
O IBC Lisbon 2021 trata-se um evento com um programa científico internacional, com a duração de dois dias e que visa fornecer informações de última geração sobre o câncer de mama, fomentando o equilíbrio entre a investigação clínica, translacional e básica, bem como, proporcionar um fórum de interação, discussão e aprendizagem para médicos e farmacêuticos hospitalares e outros especialistas (profissionais de saúde e investigadores) com especial interesse no câncer de mama. Data: de 14/10/2021 a 15/10/2021Local: OnlineEndereço: Lisboa, PortugalInvestimento/Taxa de Inscrição: 350€ (IVA incluído)Inscrições: http://www.innovationinbreastcancer.com/lisbon